OOIR: Observatory of International Research

Papers

(The H4-Index of Antiviral Research is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Editorial Board	361
Editorial Board	103
RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination	99
Editorial Board	65
Editorial Board	65
Corrigendum to “Crystal structure and cap binding analysis of the methyltransferase of langat virus” [Antivir. Res. 208 (2022) 105459]	63
Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.	61
Novel inhibitors of HSV-1 protease effective in vitro and in vivo	60
Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study	57
Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice	57
Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells	49
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier	44
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies	42
A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN	37
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2	37
Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models	37
Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs	36
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals	35
A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy	35
Chemical-induced degradation of PreS2 mutant surface antigen via the induction of microautophagy	35
A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies	35
Novel strategy for Poxviridae prevention: Thermostable combined subunit vaccine patch with intense immune response	35
Berberine promotes K48-linked polyubiquitination of HNF4α, leading to the inhibition of HBV replication	35
Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients	34
Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections	33

Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model	33
Corrigendum to “The novel therapeutic target and inhibitory effects of PF-429242 against Zika virus infection” [Antivir. Res. vol 192 (2021) 1–13/105121]	32
JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase	30
Editorial Board	30
Structural and quantitative comparison of viral infection-associated N-glycans in plasma from humans, pigs, and chickens: Greater similarity between humans and chickens than pigs	29
Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses	29